(Q36609657)

15 August 2017

0 references

Meta-analysis of clodronate and breast cancer survival (English)

1 reference

15 August 2017

1 reference

T C Ha

1

1 reference

15 August 2017

H Li

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

27 February 2007

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

96

1 reference

15 August 2017

12

1 reference

15 August 2017

1796-1801

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603661

15 August 2017

0 references

cites work

Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Clodronate : a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Bisphosphonates and metastatic breast carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Aggregate data meta-analysis with time-to-event outcomes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Quantifying heterogeneity in a meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Skeletal complications of malignancy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Clodronate for osteolytic metastases due to breast cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Extended safety profile of oral clodronate after long-term use in primary breast cancer patients

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Oral clodronate in breast cancer patients with bone metastases: a randomized study.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359972

Adjuvant clodronate therapy in patients with locally advanced breast cancer--long term results of a double blind randomized trial. Slovak Clodronate Collaborative Group

20 September 2018

1 reference

12 December 2020

Treatment of skeletal disease in breast cancer: a controlled clodronate trial

1 reference

12 December 2020

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

12 December 2020

Clodronate decreases the frequency of skeletal metastases in women with breast cancer

1 reference

12 December 2020

Detecting and describing heterogeneity in meta-analysis

1 reference

12 December 2020

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

12 December 2020

Bisphosphonates for breast cancer

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603661

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6603661

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

17325699

1 reference